BACKGROUND: Epidermal growth factor receptor (EGFR) exon 20 insertions (exon20ins) represent approximately 10% of EGFR-mutant lung adenocarcinomas, and are associated with resistance to EGFR tyrosine kinase inhibitors (TKIs). Clinical outcomes in comparison with patients with sensitizing EGFR mutations are not well established. METHODS: Patients with stage IV lung adenocarcinomas with EGFR exon20ins were identified through routine molecular testing. Clinicopathologic data were collected. Overall survival (OS) was measured from the diagnosis of stage IV disease, and in patients treated with EGFR TKIs, the time to progression (TTP) on erlotinib was measured. RESULTS: One thousand eight hundred and eighty-two patients with stage IV lung adenocarcinomas were identified: 46 patients had EGFR exon20ins (2%), and 258 patients had an EGFR exon 19 deletion (exon19del)/L858R point mutation (14%). Among 11 patients with lung adenocarcinomas with EGFR exon20ins who received erlotinib, 3 patients (27%) had a partial response (FQEA, 1; ASV, 1; and unknown variant, 1). TTP for patients with EGFR exon20ins and patients with EGFR exon19del/L858R on erlotinib were 3 and 12 months, respectively (P < .01). Responses to chemotherapy were similar for patients with lung adenocarcinomas with EGFR exon20ins and patients with lung adenocarcinomas with EGFR exon19del/L858R. Median OS from the diagnosis of stage IV disease for patients with EGFR exon20ins and patients with EGFR exon19del/L858R was 26 months (95% confidence interval, 19 months-not reached n = 46) and 31 months (95% confidence interval, 28-33 months; n = 258), respectively (P = .53). CONCLUSIONS: The majority of patients with advanced lung adenocarcinomas harboring EGFR exon20ins do not respond to EGFR TKI therapy. Standard chemotherapy should be used as first-line therapy. These patients have an OS similar to that of patients with sensitizing EGFR mutations. Individuals with certain variants such as FQEA and ASV may respond to erlotinib.
BACKGROUND:Epidermal growth factor receptor (EGFR) exon 20 insertions (exon20ins) represent approximately 10% of EGFR-mutant lung adenocarcinomas, and are associated with resistance to EGFR tyrosine kinase inhibitors (TKIs). Clinical outcomes in comparison with patients with sensitizing EGFR mutations are not well established. METHODS:Patients with stage IV lung adenocarcinomas with EGFR exon20ins were identified through routine molecular testing. Clinicopathologic data were collected. Overall survival (OS) was measured from the diagnosis of stage IV disease, and in patients treated with EGFR TKIs, the time to progression (TTP) on erlotinib was measured. RESULTS: One thousand eight hundred and eighty-two patients with stage IV lung adenocarcinomas were identified: 46 patients had EGFR exon20ins (2%), and 258 patients had an EGFR exon 19 deletion (exon19del)/L858R point mutation (14%). Among 11 patients with lung adenocarcinomas with EGFR exon20ins who received erlotinib, 3 patients (27%) had a partial response (FQEA, 1; ASV, 1; and unknown variant, 1). TTP for patients with EGFR exon20ins and patients with EGFR exon19del/L858R on erlotinib were 3 and 12 months, respectively (P < .01). Responses to chemotherapy were similar for patients with lung adenocarcinomas with EGFR exon20ins and patients with lung adenocarcinomas with EGFR exon19del/L858R. Median OS from the diagnosis of stage IV disease for patients with EGFR exon20ins and patients with EGFR exon19del/L858R was 26 months (95% confidence interval, 19 months-not reached n = 46) and 31 months (95% confidence interval, 28-33 months; n = 258), respectively (P = .53). CONCLUSIONS: The majority of patients with advanced lung adenocarcinomas harboring EGFR exon20ins do not respond to EGFR TKI therapy. Standard chemotherapy should be used as first-line therapy. These patients have an OS similar to that of patients with sensitizing EGFR mutations. Individuals with certain variants such as FQEA and ASV may respond to erlotinib.
Authors: Julian Carretero; Takeshi Shimamura; Klarisa Rikova; Autumn L Jackson; Matthew D Wilkerson; Christa L Borgman; Matthew S Buttarazzi; Benjamin A Sanofsky; Kate L McNamara; Kathleyn A Brandstetter; Zandra E Walton; Ting-Lei Gu; Jeffrey C Silva; Katherine Crosby; Geoffrey I Shapiro; Sauveur-Michel Maira; Hongbin Ji; Diego H Castrillon; Carla F Kim; Carlos García-Echeverría; Nabeel Bardeesy; Norman E Sharpless; Neil D Hayes; William Y Kim; Jeffrey A Engelman; Kwok-Kin Wong Journal: Cancer Cell Date: 2010-06-15 Impact factor: 31.743
Authors: Zengliu Su; Dora Dias-Santagata; Markeesa Duke; Katherine Hutchinson; Ya-Lun Lin; Darrell R Borger; Christine H Chung; Pierre P Massion; Cindy L Vnencak-Jones; A John Iafrate; William Pao Journal: J Mol Diagn Date: 2010-12-23 Impact factor: 5.568
Authors: Natasha Rekhtman; Paul K Paik; Maria E Arcila; Laura J Tafe; Geoffrey R Oxnard; Andre L Moreira; William D Travis; Maureen F Zakowski; Mark G Kris; Marc Ladanyi Journal: Clin Cancer Res Date: 2012-01-06 Impact factor: 12.531
Authors: Geoffrey R Oxnard; Maria E Arcila; Juliann Chmielecki; Marc Ladanyi; Vincent A Miller; William Pao Journal: Clin Cancer Res Date: 2011-07-20 Impact factor: 12.531
Authors: Takayuki Kosaka; Junko Tanizaki; Raymond M Paranal; Hideki Endoh; Christine Lydon; Marzia Capelletti; Claire E Repellin; Jihyun Choi; Atsuko Ogino; Antonio Calles; Dalia Ercan; Amanda J Redig; Magda Bahcall; Geoffrey R Oxnard; Michael J Eck; Pasi A Jänne Journal: Cancer Res Date: 2017-03-31 Impact factor: 12.701
Authors: Helena A Yu; Ken Suzawa; Emmet Jordan; Ahmet Zehir; Ai Ni; Ryan Kim; Mark G Kris; Matthew D Hellmann; Bob T Li; Romel Somwar; David B Solit; Michael F Berger; Maria Arcila; Gregory J Riely; Marc Ladanyi Journal: Clin Cancer Res Date: 2018-03-12 Impact factor: 12.531
Authors: Jonathan W Riess; David R Gandara; Garrett M Frampton; Russell Madison; Nir Peled; Jose A Bufill; Grace K Dy; Sai-Hong Ignatius Ou; Philip J Stephens; John D McPherson; Primo N Lara; Rebekah A Burich; Jeffrey S Ross; Vincent A Miller; Siraj M Ali; Philip C Mack; Alexa B Schrock Journal: J Thorac Oncol Date: 2018-07-05 Impact factor: 15.609
Authors: Jaebong Jang; Jieun Son; Eunyoung Park; Takayuki Kosaka; Jamie A Saxon; Dries J H De Clercq; Hwan Geun Choi; Junko Tanizaki; Michael J Eck; Pasi A Jänne; Nathanael S Gray Journal: Angew Chem Int Ed Engl Date: 2018-08-03 Impact factor: 15.336
Authors: Debyani Chakravarty; Jianjiong Gao; Sarah M Phillips; Ritika Kundra; Hongxin Zhang; Jiaojiao Wang; Julia E Rudolph; Rona Yaeger; Tara Soumerai; Moriah H Nissan; Matthew T Chang; Sarat Chandarlapaty; Tiffany A Traina; Paul K Paik; Alan L Ho; Feras M Hantash; Andrew Grupe; Shrujal S Baxi; Margaret K Callahan; Alexandra Snyder; Ping Chi; Daniel Danila; Mrinal Gounder; James J Harding; Matthew D Hellmann; Gopa Iyer; Yelena Janjigian; Thomas Kaley; Douglas A Levine; Maeve Lowery; Antonio Omuro; Michael A Postow; Dana Rathkopf; Alexander N Shoushtari; Neerav Shukla; Martin Voss; Ederlinda Paraiso; Ahmet Zehir; Michael F Berger; Barry S Taylor; Leonard B Saltz; Gregory J Riely; Marc Ladanyi; David M Hyman; José Baselga; Paul Sabbatini; David B Solit; Nikolaus Schultz Journal: JCO Precis Oncol Date: 2017-05-16
Authors: Nicolas Floc'h; Matthew J Martin; Jonathan W Riess; Jonathan P Orme; Anna D Staniszewska; Ludovic Ménard; Maria Emanuela Cuomo; Daniel J O'Neill; Richard A Ward; M Raymond V Finlay; Darren McKerrecher; Mingshan Cheng; Daniel P Vang; Rebekah A Burich; James G Keck; David R Gandara; Philip C Mack; Darren A E Cross Journal: Mol Cancer Ther Date: 2018-02-26 Impact factor: 6.261